entertainment -WSS

entertainment

author：focus 2025-10-01 00:59:39 - browse：25632

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

A group of advisers to the Food and Drug Administration voted in favor of Alnylam Pharmaceuticals’ treatment for a debilitating heart disease Wednesday, but only after a day-long debate challenging whether the drug’s modest observed effects were actually meaningful for patients.

The group of independent experts voted 9-3 that the benefits of Alnylam’s drug, called patisiran, outweighed its risks for patients with ATTR-CM, a progressive disease that leads to fatal heart failure if left untreated. The FDA, which is not required to follow the advice of advisers, is expected to make a final decision on patisiran by Oct. 8.

“It’s like a light wind blowing in favor of patisiran over placebo,” said David Cella, a neurologist at the Northwestern University Feinberg School of Medicine who voted in favor of patisiran. David Moliterno, a cardiologist at the University of Kentucky, added that “the good news in this story is that while there may be a small benefit, it doesn’t look like there’s a signal for harm.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： J&J to buy cancer drug developer Ambrx Biopharma

WSS

Antibiotic resistance and the global rise in human conflict

Federal weight loss drug coverage is 30 years out of date

The biotech scorecard for Q1: 17 stock

GSK Flovent asthma inhalers replaced by authorized generics

New weight loss drugs work. But how can they best be used?

How a scoliosis diagnosis changed the life of one young dancer

focus

entertainment

Wikipedia

Heart attack and stroke risk calculators need revising

The dental labor crisis is a moment of opportunity

Novavax promises a turnaround & Lilly roils the obesity market

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Psychedelics group wrestles with new pharma identity

Gilead might be held responsible for not developing a drug

FDA approval of Sarepta Duchenne genetic therapy gives me hope

BioAge raises $170M for combination therapy with Zepbound

knowledge

Robert F. Kennedy is pitching centrism on health, even on abortion

Morgan Health, with ambitious aims, wants you to know it’s still here

New weight loss drugs work. But how can they best be used?

3 medical device trends to watch in 2024

Doctors' information doesn't help them choose wisely when sick

Medicare Advantage proposed rates disappoint insurers

knowledge

focus

focus

knowledge